Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis.
BACKGROUND: Drotrecogin alfa (activated) [DrotAA] is approved for the reduction of mortality in adults with severe sepsis (sepsis with acute organ dysfunction) and high risk of death. Patients whose actual body weight was >135 kg were excluded from the
Ann Pharmacother 2005 Feb;39(2):262-7. Epub 2005 Jan 4.